86147-28-6

Basic information

• Product Name: 3-(4-CHLORO-PHENYL)-PIPERAZIN-2-ONE
• Synonyms: 3-(4-CHLORO-PHENYL)-PIPERAZIN-2-ONE;3-(4-Chlorophenyl)-2-piperazinone;3-(p-chlorophenyl)-2-Piperazinone
• CAS NO: 86147-28-6
• Molecular Formula: C₁₀H₁₁ClN₂O
• Molecular Weight: 210.66
• Mol File: 86147-28-6.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-(4-CHLORO-PHENYL)-PIPERAZIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-CHLORO-PHENYL)-PIPERAZIN-2-ONE(86147-28-6)
• EPA Substance Registry System: 3-(4-CHLORO-PHENYL)-PIPERAZIN-2-ONE(86147-28-6)

Safety Data

• Hazardous Substances Data: 86147-28-6(Hazardous Substances Data)

Usage

General Description

3-(4-Chloro-phenyl)-piperazin-2-one is a chemical compound that falls under the category of piperazines. Piperazines are a broad class of chemical compounds, many with important pharmacological properties, which contain a core piperazine functional group. This particular compound, being a chlorinated derivative, has a chlorine atom substituted on the phenyl ring. Exact properties such as boiling point, melting point, or solubility would rely largely on its specific physical and chemical properties, which are influenced by its molecular structure. Potential uses or biological activities of this compound are not readily available and would require further research, possibly including biological assays or screening. As with all chemicals, it must be handled with appropriate safety measures.

Upstream product

• 52449-43-1 (4-chloro-phenyl)-acetic acid methyl ester 
• 24091-92-7 methyl 2-bromo-2-(4-chlorophenyl)acetate 
• 107-15-3 ethylenediamine 

Downstream Products

• 769944-38-9 4-(tert-butoxycarbonyl)-3-(4-chlorophenyl)-piperazin-2-one 
• 769944-39-0 4-(tert-butoxycarbonyl)-3-(4-chlorophenyl)piperazine 

Relevant articles and documents

Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors

We herein describe the results of further evolution of glycogen synthase kinase (GSK)-3β inhibitors from our promising compounds containing a 2-phenylmorpholine moiety. Transformation of the morpholine moiety into a piperazine moiety resulted in potent GSK-3β inhibitors. SAR studies focused on the phenyl moiety revealed that a 4-fluoro-2-methoxy group afforded potent inhibitory activity toward GSK-3β. Based on docking studies, new hydrogen bonding between the nitrogen atom of the piperazine moiety and the oxygen atom of the main chain of Gln185 has been indicated, which may contribute to increased activity compared with that of the corresponding phenylmorpholine analogues. Effect of the stereochemistry of the phenylpiperazine moiety is also discussed.